BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69d9539669a06
DTSTAMP:20260410T154630
DTSTART:20190125T150000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20190125T150000
URL:https://murmitoyen.com/events/vanille/udem/detail/856796-conference-de-
 chimie-avec-le-docteur-karl-hansford
LOCATION:Pavillon Roger Gaudry – Université de Montréal\, Montréal\, Q
 C\, Canada
SUMMARY:Conférence de chimie avec le Docteur Karl Hansford
DESCRIPTION:Titre : The Antibiotic Crisis - A Confluence of Evolution and M
 isfortune
\n 
\nEndroit : Pavillon Roger-Gaudry\, Salle G-715
\n 
\nHôt
 e : William Lubell
\n 
\nrésumé : Forever in an arms race against bacte
 ria\, we now face an uncertain future as bacteria continually evolve to de
 velop resistance to our antibiotic armamentarium. This has led to an omino
 us rise of infections caused by multidrug-resistant strains of Gram-negati
 ve bacteria\, for which treatment options are limited. The phenomenon is g
 lobally recognized\, but continuous rhetoric has yet to deliver effective 
 strategies to solve this multi-faceted problem. In particular\, major scie
 ntific challenges have slowed the progression of the antibiotic pipeline\,
  particularly for Gram-negative therapies. Most antibiotics are derived fr
 om natural products\, representing a finite number of classes with associa
 ted modes of action that have inevitably fallen prey to resistance develop
 ment. To stay one step ahead in this perpetual battle\, new molecules with
  unique modes of action are desperately needed\, but finding new starting 
 points for antibiotic development is a major challenge. We have adopted se
 veral approaches to tackle these issues: we re-designed vancomycin to over
 come resistance in Gram-positive bacteria through selective targeting of t
 he bacterial membrane\; we delved into the past to “rediscoverâ€
  octapeptin\, an abandoned natural product lipopeptide with the ability 
 to overcome polymyxin-resistance\; and we have rallied the global chemical
  community to help us find new starting points for compound development by
  establishing the Community for Open Antimicrobial Drug Discovery (CO-ADD)
 .
\n 
\nBiographie : Dr Hansford is a Senior Research Officer at the Ins
 titute for Molecular Bioscience (IMB) at the University of Queensland. He 
 received his B.Sc. (Hons) and Ph.D (2000) in chemistry from the University
  of Queensland before undertaking postdoctoral studies at the University o
 f Pittsburgh and the Université de Montréal. Thereafter\, he joined Mime
 togen Pharmaceuticals (Montréal) developing peptidomimetics as a platform
  for neurotrophin mimicry\, before relocating back to Australia to lead th
 e development of novel methodology for the commercial scale production of 
 boronic acids at Boron Molecular (Melbourne). In 2011 he joined the Cooper
  group at the IMB\, where he now manages several antibiotic-based projects
 \, including the hit confirmation and validation platform of CO-ADD.
\n
\n
 Site Web du Dr Hansford
\nAnnonce PDF de la conférence
\n
\n 
\n 
\n
  
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR